Loading market dashboard
Aurinia Pharmaceuticals Inc.
AUPHHealthcareNASDAQCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share. The purchase represents 6.66% of Kevin Tang's total holdings prior to the transaction, with direct ownership unchanged at zero shares post-transaction.
Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue growth, 48% net income growth, and robust cash flow, reaffirming FY26 guidance for double-digit revenue gains. Tang Capital Management increased its stake above 10%, signaling confidence in AUPH's valuation and future pipeline or strategic optionality.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death.
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ:
Silver prices surged 7% Monday to the highest since March.
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.
Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Cronos Group (NASDAQ: CRON - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation. Institutional and Insider Ownership 36.8% of Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH - Get Free Report) (TSE: AUP) has earned an average recommendation of "Hold" from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target
SG Americas Securities LLC raised its holdings in Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) (TSE: AUP) by 69.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,224 shares of the biotechnology company's stock after purchasing an additional 55,903 shares during the
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right.
Aurinia Pharmaceuticals has undergone a major management overhaul, with fund manager and activist investor Kevin Tang appointed as the CEO. AUPH's COO and CFO have also been replaced. Lupkynis's net product sales reached $271.3M in 2025, up 25.5% YoY, with 2026 guidance for $305M–$315M, possibly conservative given the company's previous beat of initial 2025 guidance. Aritinercept will be evaluated in two autoimmune diseases, with one clinical study already underway and another set to commence in H1 2026, although the exact indications have not been disclosed.
CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following statement in response to the Company's announcement that Kevin Tang has been appointed Chief Executive Officer, effective immediately. Antoine Khalife, Founder of MKT Capital, stated: “Today marks a watershed moment for Aurinia shareholders. Since 2019,.
The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Management Transition.
